Kisspeptin-10
KISS1-derived decapeptide — GnRH pathway activator
A ten-amino-acid peptide that drives the reproductive hormone cascade by acting on the pathway above GnRH. Used in research and specialist reproductive medicine; not an approved product.
- Category
- Growth & Performance
- Half-life
- Minutes — the peptide is cleared very quickly from circulation
- Cycle length
- Not applicable — research and diagnostic administration
- Level
- advanced
Overview
Kisspeptin is the peptide product of the KISS1 gene, and its discovery clarified a question that had puzzled reproductive biology for decades: what actually triggers the pulses of gonadotrophin-releasing hormone that drive the reproductive axis. The ten-amino-acid fragment, kisspeptin-10, is the most potent naturally occurring form. It belongs in this library as a hormonal signal rather than a self-administered compound. Kisspeptin is used in reproductive research and in specialist settings to test and stimulate the axis, and its effects are immediate and measurable. Its relevance to readers is mostly explanatory: it shows how the hormones commonly manipulated with grey-market peptides are actually regulated.
How it works
Kisspeptin signalling through the KISS1R receptor is the principal upstream driver of gonadotrophin-releasing hormone release. A pulse of kisspeptin therefore produces a pulse of GnRH, followed by LH and, with repeated stimulation, FSH. Because the pathway sits above the pituitary and gonads, its effects are rapid and reversible in a way that injected gonadotrophins are not.
Reported benefits
- Rapid, dose-dependent release of LH in healthy volunteers
- Restores ovulatory cycles in some women with hypothalamic amenorrhoea
- Used experimentally to localise the source of premature puberty
- Effects are brief and rapidly reversible
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
No approved product. Research protocols in healthy volunteers used single intravenous doses of roughly 1.5 to 10 nmol/kg, and some studies used continuous infusion. Doses in women with hypothalamic amenorrhoea were individualised under specialist supervision.
Kisspeptin is used in research and specialist reproductive medicine, typically as single doses or short infusions with hormone monitoring. There is no basis for a repeated self-administered protocol.
Occasionally reported at 100–200 mcg by injection, one to three times weekly in short courses. This is among the weakest-documented community patterns in this index — treat any figure with more scepticism than most.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
Human studies have established kisspeptin's pharmacology with unusual clarity for a research peptide. Single doses in healthy men and women produce prompt, dose-dependent LH release; studies in women with hypothalamic amenorrhoea have shown restoration of ovulation in some participants; and kisspeptin administration has been used experimentally to investigate conditions such as premature ovarian insufficiency and to map the neuroendocrine control of puberty. The research is genuinely informative and the clinical role remains narrow: it is a probe and a potential therapeutic in specific reproductive disorders, not a general performance compound. Repeated self-administration would mean deliberately perturbing a tightly regulated hormonal axis with no monitoring.
Preclinical & non-clinical data
Kisspeptin-10 is the upstream trigger for GnRH release, so the mechanism is well established in reproductive endocrinology. Small human studies use it to provoke LH release in fertility research and as a diagnostic probe. Long-term safety and effects on the natural reproductive axis in healthy people have not been studied.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
Reporting is thin and mostly sits in fertility, hormone-optimisation and bodybuilding communities, where short courses are described for libido, mood and testosterone changes. The important part of these accounts is the caution that recurs in them: because kisspeptin sits upstream of the whole reproductive axis, frequent use has been reported to dull the natural signalling it is meant to amplify, and users describe needing longer breaks over time.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Flushing and transient warmth
- Brief nausea
- Headache
- No long-term safety data available
- Hormonal shifts that could disrupt the menstrual cycle
Safety notes
Hormonal manipulation of the reproductive axis without monitoring can disrupt ovulation and menstrual function. Kisspeptin has been given to humans in controlled research settings with acceptable short-term tolerability, but there is no long-term safety data and no approved product. Anyone considering it for fertility or hormonal purposes should be doing so through a reproductive endocrinologist, not a supplier.
Stacking
Not a compound to stack. Combined with other hormonal peptides it would perturb an axis whose feedback regulation makes effects difficult to predict or attribute.
Related compounds
CJC-1295
Modified GRF 1-29, CJC-1295 without DAC
Growth & Performance
A GHRH analogue built for a sharp, short pulse.
Tesamorelin
GHRH(1-44) analogue — Egrifta
Growth & Performance
The GHRH analogue with an approval and a narrow indication.
Sermorelin
GHRH(1-29) — growth hormone-releasing hormone fragment
Growth & Performance
The oldest GHRH fragment, still sold on a plausible mechanism and thin outcome data.